{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:14:49Z","timestamp":1792761289811,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11817-2","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:18:08Z","timestamp":1762957088000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The safety of cabotegravir in pregnancy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Amber","family":"Jasper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarentha","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1","key":"11817_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMp1916753","volume":"383","author":"AS Fauci","year":"2020","unstructured":"Fauci AS, Lane HC. Four decades of HIV\/AIDS\u2014much accomplished, much to do. N Engl J Med. 2020;383(1):1\u20134.","journal-title":"N Engl J Med"},{"key":"11817_CR2","unstructured":"HIV data and statistics [Internet]. World Health Organization; [cited 2023 Jul 11]. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"issue":"1","key":"11817_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41577-018-0085-4","volume":"19","author":"MP Davenport","year":"2019","unstructured":"Davenport MP, Khoury DS, Cromer D, Lewin SR, Kelleher AD, Kent SJ. Functional cure of HIV: the scale of the challenge. Nat Rev Immunol. 2019;19(1):45\u201354.","journal-title":"Nat Rev Immunol"},{"key":"11817_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s10461-016-1627-z","volume":"21","author":"FM Koechlin","year":"2017","unstructured":"Koechlin FM, Fonner VA, Dalglish SL, O\u2019Reilly KR, Baggaley R, Grant RM, Rodolph M, Hodges-Mameletzis I, Kennedy CE. Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS Behav. 2017;21:1325\u201335.","journal-title":"AIDS Behav"},{"key":"11817_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","volume":"125","author":"AS Ray","year":"2016","unstructured":"Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: a novel prodrug of Tenofovir for the treatment of human immunodeficiency virus. Antiviral Res. 2016;125:63\u201370.","journal-title":"Antiviral Res"},{"key":"11817_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-020-05255-5","volume":"20","author":"CL Naicker","year":"2020","unstructured":"Naicker CL, Mansoor LE, Dawood H, Naidoo K, Singo D, Matten D, Williamson C, Abdool Karim Q. Importance of early identification of PrEP breakthrough infections in a generalized HIV epidemic: a case report from a PrEP demonstration project in South Africa. BMC Infect Dis. 2020;20:1\u20136.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"11817_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/sajhivmed.v21i1.1152","volume":"21","author":"LG Bekker","year":"2020","unstructured":"Bekker LG, Brown B, Joseph-Davey D, Gill K, Moorhouse M, Delany-Moretlwe S, Myer L, Orrell C, Rebe K, Francois Venter WD, Wallis CL. Southern African guidelines on the safe, easy and effective use of pre-exposure prophylaxis: 2020. South Afr J HIV Med. 2020;21(1):1\u20138.","journal-title":"South Afr J HIV Med"},{"issue":"4","key":"11817_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/QAI.0000000000002042","volume":"81","author":"SK Calabrese","year":"2019","unstructured":"Calabrese SK, Willie TC, Galvao RW, Tekeste M, Dovidio JF, Safon CB, Blackstock O, Taggart T, Kaplan C, Caldwell A, Kershaw TS. Current US guidelines for prescribing HIV pre-exposure prophylaxis (PrEP) disqualify many women who are at risk and motivated to use PrEP. JAIDS J Acquir Immune Defic Syndr. 2019;81(4):395\u2013405.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"11817_CR9","first-page":"231","volume":"22","author":"KM De Cock","year":"2021","unstructured":"De Cock KM, Jaffe HW, Curran JW. Reflections on 40 years of AIDS. Advances in clinical Immunology, medical Microbiology, COVID-19, and big data. Dec. 2021;22:231\u201345.","journal-title":"Dec"},{"issue":"8","key":"11817_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1089\/aid.2018.0031","volume":"34","author":"H Janes","year":"2018","unstructured":"Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, Gilbert PB, Gray GE. Weighing the evidence of efficacy of oral PrEP for HIV prevention in women in Southern Africa. AIDS Res Hum Retroviruses. 2018;34(8):645\u201356.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"43","key":"11817_CR11","doi-asserted-by":"publisher","first-page":"e17716","DOI":"10.1097\/MD.0000000000017716","volume":"98","author":"AI Ajayi","year":"2019","unstructured":"Ajayi AI, Mudefi E, Yusuf MS, Adeniyi OV, Rala N, Ter Goon D. Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. Medicine. 2019;98(43):e17716.","journal-title":"Medicine"},{"issue":"7","key":"11817_CR12","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595\u2013608.","journal-title":"N Engl J Med"},{"key":"11817_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-019-01108-x","volume":"79","author":"KM Gibas","year":"2019","unstructured":"Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre-exposure prophylaxis. Drugs. 2019;79:609\u201319.","journal-title":"Drugs"},{"key":"11817_CR14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","volume":"60","author":"D Hodge","year":"2021","unstructured":"Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug\u2013drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60:835\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"11817_CR15","doi-asserted-by":"publisher","first-page":"e063089","DOI":"10.1136\/bmjopen-2022-063089","volume":"12","author":"YN Wu","year":"2022","unstructured":"Wu YN, Yu H, Lu L, Li X, Liu X, Cao W, Li T. Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol. BMJ Open. 2022;12(12):e063089.","journal-title":"BMJ Open"},{"issue":"12","key":"11817_CR16","doi-asserted-by":"publisher","first-page":"e814","DOI":"10.1016\/S2352-3018(22)00293-4","volume":"9","author":"E Mudimu","year":"2022","unstructured":"Mudimu E, Bershteyn A. How much could long-acting PrEP cost in South africa? Lancet HIV. 2022;9(12):e814\u20135.","journal-title":"Lancet HIV"},{"issue":"2","key":"11817_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.molmed.2022.11.003","volume":"29","author":"C Pike","year":"2023","unstructured":"Pike C, Bekker LG. Interrogating the promise of long-acting HIV pre-exposure prophylaxis. Trends Mol Med. 2023;29(2):93\u20138.","journal-title":"Trends Mol Med"},{"issue":"6","key":"11817_CR18","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JCP.0000000000000610","volume":"36","author":"P Ravenstijn","year":"2016","unstructured":"Ravenstijn P, Samtani M, Russu A, Hough D, Gopal S. Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid versus the gluteal muscle: are they therapeutically equivalent? J Clin Psychopharmacol. 2016;36(6):744\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"11817_CR19","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1007\/s10461-021-03357-y","volume":"25","author":"CT Rael","year":"2021","unstructured":"Rael CT, Lopez-R\u00edos J, McKenna SA, Das D, Dolezal C, Abascal E, Carballo-Di\u00e9guez A, Schnall R, Hope TJ, Bauermeister J, Bockting W. Transgender women\u2019s barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav. 2021;25(12):4180\u201392.","journal-title":"AIDS Behav"},{"issue":"12","key":"11817_CR20","doi-asserted-by":"publisher","first-page":"e857","DOI":"10.1016\/S2352-3018(22)00251-X","volume":"9","author":"L Jamieson","year":"2022","unstructured":"Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022;9(12):e857\u201367.","journal-title":"Lancet HIV"},{"issue":"3","key":"11817_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/QAI.0000000000000968","volume":"72","author":"AH Tran","year":"2016","unstructured":"Tran AH, Best BM, Stek A, Wang J, Capparelli EV, Burchett SK, Kreitchmann R, Rungruengthanakit K, George K, Cressey TR, Chakhtoura N. Pharmacokinetics of rilpivirine in HIV-infected pregnant women. JAIDS J Acquir Immune Defic Syndr. 2016;72(3):289\u201396.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"11817_CR22","doi-asserted-by":"publisher","unstructured":"Sahloff EG, Hamons N, Baumgartner K, Duggan JM. Is long-acting Cabotegravir a pre-exposure prophylaxis option for women of childbearing potential? Open Forum Infect Dis. 2022;9(7):ofac230. https:\/\/doi.org\/10.1093\/ofid\/ofac230.","DOI":"10.1093\/ofid\/ofac230"},{"key":"11817_CR23","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.51723.2","author":"LA Kahale","year":"2021","unstructured":"Kahale LA, Elkhoury R, El Mikati I, Pardo-Hernandez H, Khamis AM, Sch\u00fcnemann HJ, et al. Tailored PRISMA 2020 flow diagrams for living systematic reviews: a methodological survey and a proposal. F1000Res. 2021. https:\/\/doi.org\/10.12688\/f1000research.51723.2.","journal-title":"F1000Res"},{"issue":"7","key":"11817_CR24","doi-asserted-by":"publisher","first-page":"e39471","DOI":"10.1371\/journal.pone.0039471","volume":"7","author":"K Thorlund","year":"2012","unstructured":"Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, Gluud C, Devereaux PJ, Wetterslev J. Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS ONE. 2012;7(7):e39471.","journal-title":"PLoS ONE"},{"key":"11817_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-017-0630-4","volume":"6","author":"B Chen","year":"2017","unstructured":"Chen B, Benedetti A. Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes. Syst Reviews. 2017;6:1\u20139.","journal-title":"Syst Reviews"},{"issue":"10337","key":"11817_CR26","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"issue":"11","key":"11817_CR27","doi-asserted-by":"publisher","first-page":"e1002690","DOI":"10.1371\/journal.pmed.1002690","volume":"15","author":"RJ Landovitz","year":"2018","unstructured":"Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690.","journal-title":"PLoS Med"},{"issue":"11","key":"11817_CR28","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","volume":"8","author":"H Jaeger","year":"2021","unstructured":"Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8(11):e679\u201389.","journal-title":"Lancet HIV"},{"issue":"9","key":"11817_CR29","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","volume":"10","author":"MN Ramgopal","year":"2023","unstructured":"Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and Tenofovir Alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. Lancet HIV. 2023;10(9):e566\u201377.","journal-title":"Lancet HIV"},{"issue":"4","key":"11817_CR30","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","volume":"8","author":"C Orkin","year":"2021","unstructured":"Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, Degen O, Garc\u00eda JG, Morell EB, Tan DH, D\u2019Amico R. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185\u201396.","journal-title":"Lancet HIV"},{"issue":"2","key":"11817_CR31","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hiv.13370","volume":"24","author":"R D\u2019Amico","year":"2023","unstructured":"D\u2019Amico R, Cenoz Gomis S, Moodley R, Van Solingen-Ristea R, Baugh B, Van Landuyt E, Van Eygen V, Min S, Cutrell A, Foster C, Chilton D. Compassionate use of long\u2010acting cabotegravir plus rilpivirine for people living with HIV\u20101 in need of parenteral antiretroviral therapy. HIV Med. 2023;24(2):202\u201311.","journal-title":"HIV Med"},{"issue":"8","key":"11817_CR32","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S2352-3018(19)30147-X","volume":"6","author":"S Nachman","year":"2019","unstructured":"Nachman S, Townsend CL, Abrams EJ, Archary M, Capparelli E, Clayden P, Lockman S, Jean-Philippe P, Mayer K, Mirochnick M, McKenzie-White J. Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research priorities. Lancet HIV. 2019;6(8):e552\u20138.","journal-title":"Lancet HIV"},{"issue":"S2","key":"11817_CR33","first-page":"e25927","volume":"25","author":"EJ Abrams","year":"2022","unstructured":"Abrams EJ, Penazzato M. Disrupting the status quo to achieve early inclusion of pregnant women in studies of new agents for prevention and treatment of HIV infection. Afr J Reprod Gynaecol Endoscopy. 2022;25(S2):e25927.","journal-title":"Afr J Reprod Gynaecol Endoscopy"},{"issue":"5","key":"11817_CR34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s11904-022-00616-y","volume":"19","author":"UM Parikh","year":"2022","unstructured":"Parikh UM, Koss CA, Mellors JW. Long-acting injectable cabotegravir for HIV prevention: what do we know and need to know about the risks and consequences of cabotegravir resistance? Curr HIV\/AIDS Rep. 2022;19(5):384\u201393.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"11817_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","volume":"80","author":"AI Rana","year":"2020","unstructured":"Rana AI, Castillo-Mancilla JR, Tashima KT, Landovitz RL. Advances in long-acting agents for the treatment of HIV infection. Drugs. 2020;80(6):535\u201345.","journal-title":"Drugs"},{"issue":"9","key":"11817_CR36","doi-asserted-by":"publisher","first-page":"E217","DOI":"10.1503\/cmaj.191227","volume":"192","author":"J Zipursky","year":"2020","unstructured":"Zipursky J, Loutfy M. Dolutegravir for pregnant women living with HIV. CMAJ. 2020;192(9):E217\u20138.","journal-title":"CMAJ"},{"issue":"3","key":"11817_CR37","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1016\/S2352-3018(21)00280-0","volume":"9","author":"DL Davey","year":"2022","unstructured":"Davey DL, Bekker LG, Bukusi EA, Chi BH, Delany-Moretlwe S, Goga A, Lyerly AD, Mgodi NM, Mugo N, Myer L, Noguchi LM. Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. Lancet HIV. 2022;9(3):e214\u201322.","journal-title":"Lancet HIV"},{"key":"11817_CR38","doi-asserted-by":"crossref","unstructured":"Nayan MU, Sillman B, Hasan M, Deodhar S, Das S, Sultana A, Le NT, Soriano V, Edagwa B, Gendelman HE. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Adv Drug Deliv Rev. 2023;13:115009.","DOI":"10.1016\/j.addr.2023.115009"},{"issue":"9","key":"11817_CR39","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","volume":"59","author":"AT Podany","year":"2020","unstructured":"Podany AT, Scarsi KK, Pham MM, Fletcher CV. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review. Clin Pharmacokinet. 2020;59(9):1085\u2013107.","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"11817_CR40","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/ajhp\/zxac201","volume":"79","author":"C Prather","year":"2022","unstructured":"Prather C, Jeon C. Cabotegravir: the first long-acting injectable for HIV pre-exposure prophylaxis. Am J Health-System Pharm. 2022;79(21):1898\u2013905.","journal-title":"Am J Health-System Pharm"},{"issue":"9","key":"11817_CR41","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3390\/pharmaceutics14091761","volume":"14","author":"H Mohan","year":"2022","unstructured":"Mohan H, Atkinson K, Watson B, Brumme CJ, Serghides L. A Pharmacokinetic dose-optimization study of cabotegravir and bictegravir in a mouse pregnancy model. Pharmaceutics. 2022;14(9):1761.","journal-title":"Pharmaceutics"},{"issue":"3","key":"11817_CR42","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/ijms24031994","volume":"24","author":"D Zizioli","year":"2023","unstructured":"Zizioli D, Zanella I, Mignani L, Degli Antoni M, Castelli F, Quiros-Roldan E. Cabotegravir exposure of zebrafish (Danio rerio) embryos impacts on neurodevelopment and behavior. Int J Mol Sci. 2023;24(3):1994.","journal-title":"Int J Mol Sci"},{"key":"11817_CR43","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40262-018-0684-z","volume":"58","author":"R van der Gali\u00ebn","year":"2019","unstructured":"van der Gali\u00ebn R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM. Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps. Clin Pharmacokinet. 2019;58:309\u201323.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"11817_CR44","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/FTD.0000000000000684","volume":"42","author":"D Cattaneo","year":"2020","unstructured":"Cattaneo D, Baldelli S, Cozzi V, Clementi E, Marriott DJ, Gervasoni C. Impact of therapeutic drug monitoring of antiretroviral drugs in routine clinical management of people living with HIV: a narrative review. Ther Drug Monit. 2020;42(1):64\u201374.","journal-title":"Ther Drug Monit"},{"issue":"8","key":"11817_CR45","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1016\/j.clinthera.2017.05.290","volume":"39","author":"I Kacirova","year":"2017","unstructured":"Kacirova I, Grundmann M. Importance of TDM during pregnancy and breastfeeding. Clin Ther. 2017;39(8):e92\u20133.","journal-title":"Clin Ther"},{"issue":"7","key":"11817_CR46","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s40267-021-00847-w","volume":"37","author":"C Fenton","year":"2021","unstructured":"Fenton C, Lee A, Al-Salama ZT. Integrase strand transfer inhibitors can simplify HIV treatment. Drugs Therapy Perspect. 2021;37(7):300\u201312.","journal-title":"Drugs Therapy Perspect"},{"issue":"5","key":"11817_CR47","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/hiv.13439","volume":"24","author":"P Patel","year":"2023","unstructured":"Patel P, Ford SL, Baker M, Meyer C, Garside L, D\u2019Amico R, Van Solingen-Ristea R, Crauwels H, Polli JW, Seal C. Yaguee Munoz I. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long\u2010acting cabotegravir and rilpivirine in clinical trials. HIV Med. 2023;24(5):568\u201379.","journal-title":"HIV Med"},{"issue":"1","key":"11817_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ogc.2022.10.013","volume":"50","author":"KM Brooks","year":"2023","unstructured":"Brooks KM, Scarsi KK, Mirochnick M. Antiretrovirals for human immunodeficiency virus treatment and prevention in pregnancy. Obstet Gynecol Clin. 2023;50(1):205\u201318.","journal-title":"Obstet Gynecol Clin"},{"key":"11817_CR49","doi-asserted-by":"publisher","first-page":"e26115","DOI":"10.1002\/jia2.26115","volume":"26","author":"NM Mgodi","year":"2023","unstructured":"Mgodi NM, Murewanhema G, Moyo E, Samba C, Musuka G, Dzinamarira T, Brown JM. Advancing the use of Long-Acting extended delivery formulations for HIV prevention in sub\u2010Saharan africa: challenges, opportunities, and recommendations. J Int AIDS Soc. 2023;26:e26115.","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"11817_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/COH.0000000000000708","volume":"17","author":"SH Bares","year":"2022","unstructured":"Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS. 2022;17(1):22\u201331.","journal-title":"Curr Opin HIV AIDS"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11817-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:03:24Z","timestamp":1762963404000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11817"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11817-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"29 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1550"}}